La Vanguardia publishes on Sunday 18th of December edition that The Center of Genetic Engineering and Biotecnology (CIGB-Biocubafarma) and our spin-off Nanomol Technologies start to clinically validate a new drug that aims at improving the healing of diabetic foot ulcers and preventing amputation.